Medicxi — Full Portfolio

Vaxcyte is a biotech company developing vaccines to treat or prevent serious infectious diseases.

BiotechDeep TechHealthtechSouth San Francisco, US

Grant Pickering(Chief Executive Officer, Director and Co-Founder)Jeff Fairman(Vice President of Research and Co-Founder)Ashish Khanna(Executive Officer)

BoardTracy Saxton(Director)William Newell(Director)KVKurt von Emster(Director)in

Board seatMSMoncef Slaoui· per SEC Form D

Co-investorsABAbingworthCTCTI Life Sciences Fund L.P.FOForesite CapitalFRFrazier Life SciencesJAJanus Henderson InvestorsLOLongitude Capital+4 more

Aura Biosciences develops Virus-Like Drug Conjugates (VDCs), a platform using Virus-Like Particles conjugated with drugs or loaded with nucleic acids to target solid tumors.

BiotechHealthtechMedical DevicesCambridge, US

Elisabet de los Pinos, Ph.D.(Executive Officer, Director)EDElisabet de los Pinos(Founder)inMichael Wyzga(Executive Officer)Dale Pfost, Ph.D.(Director)Alan E. Walts, Ph.D.(Director)Lewis Geffen(Executive Officer)

Co-investorsADAdvent Life SciencesCHChiesi VenturesCOColumbus Venture PartnersDRDroia VenturesFOForesite CapitalJAJazzya Investments+6 more

Evotec is a drug discovery and development company that provides integrated R&D services across modalities, from small molecules to biotherapeutics, working with partners to advance new medicines.

BiotechHealthtech

Co-investorsAVaVenture

Vaxcyte develops broad-spectrum vaccines to prevent bacterial infections, using a cell-free protein synthesis platform and synthetic chemistry techniques.

BiotechHealthtech

GPGrant Pickering(Founder)in

Co-investorsBIBioRock VenturesCTCTI Life Sciences Fund L.P.FOForesite CapitalFRFrazier Life SciencesLOLongitude CapitalPIPivotal Life Sciences+3 more

Rivus Pharmaceuticals develops mitochondrial-targeted therapies to treat cardiometabolic diseases.

BiotechDigital HealthHealthtechMedical DevicesCharlottesville, US

Francisco Portell(Co-founder & Vice President, Pharmaceutical Development)ACAllen Cunningham(Co-founder & Chief Operating Officer)inNancy Hargreaves(Executive Officer)JDJayson Dallas(Executive Officer, Director)inSKShaharyar Khan(Co-founder & Chief Scientific Officer)in

Board seatFDFrancesco De Rubertis· per SEC Form D

Co-investorsBABain Capital Life SciencesLOLongitude CapitalRARA Capital

Breakpoint Therapeutics is a biotech company focused on oncology drug discovery and development centered on DNA damage response (DDR) mechanisms.

BiotechHealthtechMedical Devices

Daniel Speidel(Co-founder & Managing Director)Jon Hollick(Co-founder & Managing Director)

Co-investorsTATaiho Ventures, LLCBIBiotechnology Value Fund

Dalriada is a contract research organization providing integrated small molecule drug discovery services for global biotech and pharmaceutical companies.

BiotechDeep TechMedical DevicesToronto, CA

Diana(Co-founder and Chief Executive Officer)Patrick(Co-founder and Chief Scientific Director)

Co-investorsTOToronto Innovation Acceleration Partners

Ethyreal Bio is a biopharmaceutical company developing medicines for people with Thyroid Eye Disease and Graves' Disease.

BiotechHealthtechCambridge, US

NKNiranjan Kameswaran(Chief Executive Officer)inJSJessica Stromme(Chief Development Officer)inKFKelly Foster(Chief Scientific Officer)inSHStephen Huang(Senior Vice President, Head of Clinical Development)in

BoardSRSimon Read(Chairman of the Board and Independent Board Member)in

Co-investorsATAtlas VentureAVAvoro Capital Advisors

Levicept is a company in the life sciences sector with backing from prominent healthcare and pharmaceutical investors including Medicxi, Pfizer Ventures, Gilde Healthcare, and Advent Life Sciences.

BiotechHealthtechMedical Devices

Simon Westbrook(Founder and CSO)in

Co-investorsADAdvent Life SciencesGIGilde HealthcareINIndex VenturesPFPfizer VenturesPFPfizer Venture InvestmentsRERedwood Ventures

Ottimo is a biotech company developing oncology and immuno-oncology therapeutics, including antibody-based cancer treatments.

BiotechHealthtech

Jonny Finlay(Founder and Chief Scientific Advisor)DEDavid Epstein(Chair & Chief Executive Officer)inMSMehdi Shahidi(Head of Development & Chief Medical Officer)Ling Zeng(General Counsel and EVP of Execution)inSpencer Fisk(Chief Technical and Quality Officer)

Co-investorsOROrbiMedSASamsara BioCapitalAVAvoro Capital AdvisorsJMJMI Equity

Altesa BioSciences is a clinical-stage pharmaceutical company developing vapendavir, an orally administered antiviral targeting rhinovirus infections in patients with chronic lung diseases such as COPD and asthma.

BiotechHealthtechCollege Park, US

JCJohn Clerici(Executive Officer)inAndrew Drechsler(Executive Officer)Brett Giroir(Executive Officer, Director)

BoardNWNicholas Williams(Director)JEJon Edwards(Director)in

Board seatMSMoncef Slaoui· per SEC Form D

Co-investorsGRGRA VentureFOForbionPIPitangoSASanofi Ventures

Zephyr AI is a healthcare technology company.

AI & Machine LearningBiotechDigital HealthDallas, US

GVGrant Verstandig(Director)inYisroel Brumer(Director)Jeff Sherman(Executive Officer)David Morgan(Executive Officer)KSKen Samet(Director)Sol Barer(Director)

Board seatMSMoncef Slaoui· per SEC Form D · $120.7M raise · filed Mar 2024

Co-investorsMEMerck Global Health Innovation FundMSMSD Global Health Innovation FundRERed Cell IncubationRERevolution

Abivax develops obefazimod, an orally administered small molecule drug candidate with a novel mechanism of action targeting microRNA biology to treat chronic inflammatory diseases including ulcerative colitis and Crohn's disease.

BiotechHealthtechMedical DevicesParis, FR

MDMarc de Garidel(CEO)in

Co-investorsANAndera PartnersCLClaret Capital PartnersSASamsara BioCapitalSOSofinnova PartnersTRTruffle CapitalMOMorgan Stanley

Aura provides AI-powered digital security and protection services for families and individuals across all ages.

AI & Machine LearningConsumerCybersecurityDigital HealthWellness & FitnessBoston, US

HRHari Ravichandran(Founder)inBDBrian DeCenzo(President & Chief Financial Officer)inTCThomas Clayton(President & Chief Operating Officer)AMAdam Medros(Chief Product Officer)inSarah Cherng(Chief AI Officer)KLKristin Lewis(Chief Product Officer (prior to May 2026 CPO reorganization; promoted from SVP Product, May 2022))in

Co-investorsACAccelGEGeneral CatalystGRGranite HillMAMachina VenturesPAPartech VenturesSISignalFire+7 more

Centessa is a biopharmaceutical company developing an Orexin Receptor 2 Agonist program aimed at treating sleep-wake, neurological, neurodegenerative, and neuropsychiatric disorders.

BiotechHealthtech

Co-investorsADAdvent Life SciencesECEcoR1 CapitalFOForesite CapitalLILifeSci Venture PartnersOBOberland CapitalSCScion Life Sciences+4 more

Curevo Vaccine is a biotech company developing next-generation non-mRNA vaccines, with a focus on infectious diseases.

BiotechHealthtech

GSGeorge Simeon(CEO)inGregory S. Curhan(CFO)GDGuy De La Rosa(CMO)in

Co-investorsADAdjuvant CapitalOROrbiMedRARA CapitalSASanofi VenturesHBHBM Healthcare InvestmentsJAJanus Henderson Investors

Diasome develops metabolic therapies using its HDV platform to enable targeted drug delivery for treating diabetes, obesity, and metabolic diseases.

BiotechHealthtechMedical Devices

RGRobert Geho(Co-Founder, Chief Executive Officer)inW. Blair Geho(Co-Founder, Chief Scientific Officer)in

Co-investorsJDJDRF T1D Fund

Fore Biotherapeutics is a clinical-stage oncology company developing targeted cancer therapies, including its lead plixorafenib program.

BiotechHealthtechMedical DevicesPhiladelphia, US

Co-investorsHBHBM Healthcare InvestmentsHBHBM PartnersLGLG Technology VenturesNONovartis Venture FundOROrbiMedPOPontifax Venture Capital+4 more

Imhotex is a biotech company focused on drug development, managed by experienced professionals in therapeutic discovery and clinical advancement.

BiotechHealthtechCambridge, GB

Robert W. Schroff(Chief Operating Officer)

BoardDJDavid J. Grainger(Chairman)in

Therapeutics company with an active clinical development program.

Co-investorsANAngel Physicians FundCICincyTech

Nira provides software tools that replicate ISO interconnection study processes for power generation developers and grid operators to evaluate transmission injection capacity and interconnection feasibility.

Advanced ManufacturingCleantechClimate TechData & InfrastructureEnergyEnterprise SoftwareSaaS

CAChris Ariante(Founder)inACAndy Chen(Founder)inAMAndrew Martin(Founder)inAmir(Vice President of Interconnection)in

Co-investorsASASDF VenturesBEBeta CapitalDIDivide by ZeroENEnergize CapitalY Y Combinator

Phathom Pharmaceuticals is a pharmaceutical company that develops and markets prescription treatments, including VOQUEZNA (vonoprazan) for gastrointestinal conditions, in the U.S. market.

BiotechHealthtech

Mr. Basta(CEO)

Co-investorsCACatalys PacificFRFrazier Life SciencesNENew Enterprise Associates (NEA)ASAstellas Venture Management LLC

RAPT Therapeutics is a clinical-stage biopharmaceutical company developing therapeutics that target the immune system to treat inflammatory and immunologic diseases.

BiotechHealthtech

Co-investorsFOForesite CapitalFRFrazier Life SciencesGVGV (Google Ventures)KLKleiner PerkinsSOSolasta VenturesTHThe Column Group+1 more

SynOx Therapeutics develops emactuzumab, a monoclonal antibody treatment for tenosynovial giant cell tumours (TGCT) and macrophage-mediated diseases.

BiotechHealthtechMedical Devices

RBRay Barlow(Chief Executive Officer)in

Co-investorsHEHealthCapBIBioqube VenturesFOForbionGIGimvRERed Tree Venture

T-Cypher Bio develops drugs with curative potential, focusing on antibody development, T cell biology, and TCR discovery.

AI & Machine LearningBiotechDeep Tech

Co-investorsFUFuture Planet CapitalLILifeArc VenturesOXOxford Science EnterprisesPEPerivoli Innovations

Ultrahuman makes wearable and consumer health devices — including the Ring AIR smart ring, continuous glucose monitoring, red light therapy, sleep monitors, and blood biomarker testing — paired with an app for sleep, metabolic, and recovery tracking.

Digital HealthHardwareWellness & FitnessBengaluru, IN

MKMohit Kumar(Founder)inVSVatsal Singhal(Founder)inMohit Kumar Vatsal Singhal(Founder)

Co-investorsALAlpha Wave GlobalMAMars Shot VenturesRARajul Sandeep JhaveriBABalaji SrinivasanBLBlume VenturesISiSeed+3 more

Vaderis develops a first-of-its-kind oral therapy for hereditary hemorrhagic telangiectasia (HHT), a rare vascular disease with no existing approved treatments.

BiotechHealthtechMedical Devices

Co-investorsDRDroia VenturesEQEQT Life SciencesGOGoldman Sachs

AI & Machine LearningBiotechHealthtech

PartnerGMGiovanni Mariggi· led

Co-investorsAVAvoro Capital AdvisorsTCTCG CrossoverUNUniQuest Extension Fund (UEF)VEvenBio PartnersJMJMI Equity

Xenikos was a clinical-stage biotech developing T-Guard, an immune-system "reset" therapy aimed at life-threatening immune conditions such as acute graft-versus-host disease, transplant rejection, and severe autoimmune diseases.

BiotechHealthtech